dc.contributor.author | Karadogan, I. | |
dc.contributor.author | Sonmez, M. | |
dc.contributor.author | Gulbas, Z. | |
dc.contributor.author | Tekgunduz, E. | |
dc.contributor.author | Kaya, A. H. | |
dc.contributor.author | Ozbalak, M. | |
dc.contributor.author | Kaynar, L. | |
dc.contributor.author | Yildirim, R. | |
dc.contributor.author | Arat, M. | |
dc.contributor.author | Tastemir, N. | |
dc.contributor.author | Bekoz, H. | |
dc.contributor.author | Karadurmus, N. | |
dc.contributor.author | Paydas, S. | |
dc.contributor.author | Turker, A. | |
dc.contributor.author | Toptas, T. | |
dc.contributor.author | Tuglular, T. Firatli | |
dc.contributor.author | Ferhanoglu, B. | |
dc.contributor.author | Demirkol, O. | |
dc.contributor.author | Demirkurek, H. C. | |
dc.contributor.author | Yilmaz, M. | |
dc.contributor.author | Toprak, S. K. | |
dc.contributor.author | Koseoglu, F. D. | |
dc.contributor.author | Demirkaya, M. | |
dc.contributor.author | Barista, I. | |
dc.contributor.author | Hacioglu, S. Kabukcu | |
dc.contributor.author | Dogu, M. H. | |
dc.contributor.author | Ozcan, M. | |
dc.contributor.author | Yuksel, M. Kurt | |
dc.contributor.author | Turgut, M. | |
dc.contributor.author | Abali, H. | |
dc.contributor.author | Ozkocaman, V. | |
dc.contributor.author | Tanrikulu, F. Pepedil | |
dc.date.accessioned | 2021-03-03T11:02:47Z | |
dc.date.available | 2021-03-03T11:02:47Z | |
dc.date.issued | 2017 | |
dc.identifier.citation | Bekoz H., Karadurmus N., Paydas S., Turker A., Toptas T., Tuglular T. F. , Sonmez M., Gulbas Z., Tekgunduz E., Kaya A. H. , et al., "Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience", ANNALS OF ONCOLOGY, cilt.28, sa.10, ss.2496-2502, 2017 | |
dc.identifier.issn | 0923-7534 | |
dc.identifier.other | av_25cf1c15-6345-46cf-8c22-8e8e956b7c69 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/30315 | |
dc.identifier.uri | https://doi.org/10.1093/annonc/mdx341 | |
dc.description.abstract | Background: Reed-Sternberg cells of classical Hodgkin's lymphoma (cHL) are characterized by genetic alterations at the 9p24.1 locus, leading to over-expression of programmed death-ligand 1 and 2. In a phase 1b study, nivolumab, a PD-1-blocking antibody, produced a high response in patients with relapsed or refractory cHL, with an acceptable safety profile. | |
dc.language.iso | eng | |
dc.subject | Tıp | |
dc.subject | Onkoloji | |
dc.subject | İç Hastalıkları | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | Sağlık Bilimleri | |
dc.subject | ONKOLOJİ | |
dc.subject | Klinik Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.title | Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience | |
dc.type | Makale | |
dc.relation.journal | ANNALS OF ONCOLOGY | |
dc.contributor.department | İstanbul Medipol Üniversitesi , , | |
dc.identifier.volume | 28 | |
dc.identifier.issue | 10 | |
dc.identifier.startpage | 2496 | |
dc.identifier.endpage | 2502 | |
dc.contributor.firstauthorID | 246823 | |